Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00648193 | Fasting Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg | EARLY_PHASE1 | COMPLETED | 36 | — | — | Dec 1, 2006 | Jan 1, 2007 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Paroxetine hydrochloride 40 mg tablet |
| 2 | ACTIVE_COMPARATOR | Paxil® 40 mg Table |
| Name | Type | Description |
|---|---|---|
| Paroxetine hydrochloride 40 mg tablet | DRUG | 40mg, single dose fasting |
| Paxil® 40 mg Table | DRUG | 40mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or female of non-childbearing potential. 1. Women will not be considered of childbearing potential if one of the following is reported and documented on the medical history: 1. postmenopausal with an absence of menses for a...